Company: Goldfinch Bio
Job title: Chief Medical Officer
Dr. Czerwiec joined Goldfinch Bio from Otsuka Pharmaceutical Development & Commercialization, Inc. where he was most recently Vice President, Global Clinical Development leading their Cardio-Renal and Metabolic/Medicine group. During his 20-year tenure at Otsuka he was a key contributor to multiple drug approvals and led the global tolvaptan program in autosomal dominant polycystic kidney disease (ADPKD). During his career Dr. Czerwiec has been an active supporter of kidney disease-related research including the Critical-Path’s PKD Outcomes Consortium, Kidney Drug Development Tools Summit and ADPKD Summit. He has contributed to the National Kidney Foundation’s Patient Reported Outcome Initiative and ASN’s Kidney Health Initiative. Dr. Czerwiec earned his M.D. and a Ph.D. in Biochemistry and Molecular Biology and conducted his internal medicine residency at the University of Miami Miller School of Medicine before completing his post-doctoral training in translational research through a fellowship in Adult Endocrinology and Metabolism at the National Institutes of Health (NIH) (NICHD & NIDDK).